We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Avandia Bigger Heart Risk Than Competitor: Study

Law360 (November 26, 2008, 12:00 AM EST) -- GlaxoSmithKline PLC's popular diabetes drug Avandia may pose a greater risk of death and heart failure than Takeda Pharmaceutical Co. Ltd.'s competing drug Actos, according to a recent study.

The study,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.